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Abstract 53 
Background: Hyperkalemia is a common comorbidity in patients with heart failure with reduced 54 
ejection fraction (HFrEF). Whether it affects the use of RAAS-inhibitors and thereby negatively 55 
impacts outcome is unknown. Therefore, we investigated the association between potassium 56 
and uptitration of ACE-inhibitor/ARB and its association with outcome.  57 
Methods and results: Out of 2,516 patients from the BIOSTAT-CHF study, potassium levels 58 
were available in 1,666 patients with HFrEF. These patients were sub-optimally treated with 59 
ACEi/ARB or beta-blockers and were anticipated and encouraged to be uptitrated. Potassium 60 
levels were available at inclusion and 9 months. Outcome was a composite of all-cause 61 
mortality and HF-hospitalization at 2 years.  62 
Patients were 67±12 years old and 77% was male. At baseline, median serum potassium 63 
was 4.2(3.9–4.6) mEq/L. After 9 months, 401 (24.1%) patients were successfully uptitrated for 64 
ACEi/ARB. During this period, mean serum potassium increased by 0.16±0.66 mEq/L (p<0.001). 65 
Baseline potassium was an independent predictor for lower obtained dosages of ACEi/ARB (OR 66 
0.70; 95%CI 0.51–0.98). An increase in potassium was not associated with adverse outcomes 67 
(HR 1.15; 95%CI 0.86–1.53). No interaction was found between baseline potassium, potassium 68 
increase during uptitration or potassium at 9 months and an increase of dose of ACEi/ARB for 69 
outcome (pinteraction for all >0.5). 70 
Conclusion: Higher potassium levels are an independent predictor of enduring lower dosages of 71 
ACEi/ARB. Higher potassium levels do not attenuate the beneficial effects of uptitration 72 
ACEi/ARB. 73 
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MRA – Mineralocorticoid Receptor Antagonist 88 
NT-proBNP – N-terminal prohormone of Brain Natriuretic Peptide 89 
RAASi – Renin Angiotensin Aldosterone System-Inhibitors  90 
91 
Introduction 92 
Heart failure (HF) is associated with high mortality and morbidity (1). Current treatment 93 
possibilities for HF patients with a reduced ejection fraction (HFrEF) include ACE-inhibition 94 
(ACEi), angiotensin-receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA) and 95 
beta-blockers. These treatments have shown to improve outcomes for patients with HFrEF (2-96 
5). Unfortunately, administration of recommended doses of guideline directed medication is 97 
not often achieved (6,7).  98 
 In the general population, hyperkalemia is common and may negatively impact 99 
administration of adequate dosages of ACEi and ARB (8). Unfortunately, knowledge on this 100 
association in patients with HF is absent. Additionally, hyperkalemia is associated with worse 101 
outcomes and potassium levels are therefore closely monitored during increase of the doses of 102 
inhibitors of the RAAS system in clinical trials (9-12). Both hyperkalemia as well as the effect of 103 
hyperkalemia on tolerating higher doses of RAAS inhibitors can severely impede outcomes and 104 
interfere with their survival benefit (8,13). 105 
 Currently, no data is available on the independent association of potassium levels (or 106 
potassium change during treatment) and the achieved dose of ACEi/ARB. Additionally, limited 107 
data is available on the interaction between ACEi/ARB and the association between 108 
hyperkalemia and clinical outcome in patients with HFrEF (14). Therefore, we studied the 109 
association between serum potassium levels and successful uptitration of ACEi/ARB to HF 110 
guideline-directed dosages in the BIOSTAT-CHF cohort, which was specially designed to study 111 
effects of uptitration (15). Furthermore, we studied the interaction between guideline-directed 112 
treatment and hyperkalemia on outcomes. 113 
Methods 114 
Study cohort 115 
For the present study, data from the BIOlogy Study to TAilored Treatment in Chronic Heart 116 
Failure (BIOSTAT-CHF), an international, multicenter, prospective, observational study was 117 
investigated. Patients received ≤50% of target dosages of ACEi/ARBs and/or beta-blockers at 118 
time of inclusion and treating physicians anticipated and encouraged an increase of fraction 119 
target dose of ACEi/ARBs and/or beta-blockers to guideline directed levels. Patients were 120 
included as in- or outpatients. Potassium was measured at time of inclusion. The first 3 months 121 
after inclusion were considered as an active uptitration period, followed by a stabilization 122 
period of 6 months. Detailed description of the rationale, design, and implementation of the 123 
BIOSTAT-CHF study has been reported elsewhere (15). 124 
 For the current study, only HF patients with HFrEF (LVEF<40%) with available potassium 125 
levels at baseline were included. Out of 2,516 patients from the original study cohort, 697 126 
patients with a preserved or unknown ejection fraction were excluded. Of the remaining 1,819 127 
patients, serum potassium levels were measured in 1,666 patients. Potassium measurements at 128 
9 months were available in 918 patients (Supplementary figure 1).  129 
 130 
Definitions and study endpoints 131 
Potassium levels were classified according to clinical reference ranges, i.e. hypokalemia; <3.5 132 
mEq/L, normokalemia; 3.5 - 5.0 mEq/L, and hyperkalemia; >5.0 mEq/L (16). We defined 133 
successful uptitration as an increase of beta-blockers and ACEi/ARB if patients obtained over 134 
50% of the target dose at 9 months of follow-up and the administered dose at 9 months was 135 
greater than the dose administered at baseline according to the ESC-guidelines (17). Patients 136 
who died between baseline and 9 months (N=203) were excluded from this analysis 137 
(supplementary figure 1). Patients receiving equal guideline recommended target doses (i.e. >= 138 
100%) at baseline and 9 months were classified as successfully uptitrated patients. Patients 139 
receiving ≤ 50% of the guideline-recommended dose were labeled not successfully uptitrated 140 
(Supplementary figure 2). In sensitivity analysis, we did not include baseline doses and only 141 
tested for administered doses of ACEi/ARBs and beta-blocker at three months (18). The primary 142 
endpoint for outcome analyses of this study was a combined endpoint of all-cause mortality 143 
and HF related hospitalizations at 2 years. HF related hospitalizations were determined by the 144 
enrolling investigator.  145 
 146 
Statistical analysis 147 
For baseline characteristics, study results for continuous variables are presented as the mean (± 148 
standard deviation), medians (+ interquartile ranges) or numbers with percentages where 149 
appropriate. Baseline characteristics were stratified by serum potassium levels in hypokalemia 150 
(<3.5 mEq/L), normokalemia (3.5-5.0 mEq/L), and hyperkalemia (>5.0 mEq/L), respectively. An 151 
increase or decrease in potassium between baseline and 9 months was determined as more 152 
than a 0.1 mEq/L difference between baseline and 9 months. Intergroup differences between 153 
more than two groups were tested using the one-way analysis of variance (ANOVA); Kruskal-154 
Wallis test or chi2-test where appropriate. Q-Q plots and histograms were used to visually test 155 
all variables for normality. Normality was tested using the Kolmogorov-Smirnov test, when 156 
necessary. For further analyses, skewed variables were log-transformed to achieve normal 157 
distribution. 158 
 Relationship of potassium levels with successful uptitration between baseline and 9 159 
months was studied using logistic regression. In a stepwise manner, this was corrected for 160 
clinically relevant confounders of potassium, which age, sex, eGFR, systolic blood pressure, 161 
diabetes mellitus, and ACEi/ARB usage at 9 months (in case of beta-blocker uptitration) or beta-162 
blocker usage at 9 months (in case of ACEi/ARB uptitration). Additionally, we corrected for 163 
uptitration models that best predicted successful uptitration rates in this cohort for beta-164 
blockers and ACEi/ARB (18). For beta-blockers, these include age, country of inclusion, diastolic 165 
blood pressure, heart rate, and signs of pulmonary congestion. For ACEi/ARB these include sex, 166 
BMI, eGFR, alkaline phosphatase, and country of inclusion, as published previously (18). The 167 
association between potassium and outcome is depicted using Kaplan-Meier curves for 168 
potassium levels at baseline, potassium levels at 9 months and a change of potassium levels 169 
between baseline and 9 months. A difference in survival was tested using the log-rank test. To 170 
investigate the association with survival of potassium in multivariable analyses, Cox regression 171 
analyses were performed correcting for clinically relevant variables, these include age, sex, 172 
eGFR, hypertension, diabetes mellitus, and ACEi/ARB or beta-blocker use at 9 months. 173 
Interaction analyses were performed to investigate the interaction between successful 174 
uptitration and its association with outcome of potassium levels (as a continuous variable).  175 
 A two-sided p-value <0.05 was considered statistically significant and 95% CI were 176 
presented for all odds ratios. For statistical analyses, Stata MP13 (StataCorp. 2013. Stata 177 
Statistical Software: Release 13. College Station, TX: StataCorp LP.) was used.  178 
Results 179 
Baseline characteristics 180 
Out of a total of 1,666 patients, 114 patients (6.9%) had potassium levels below 3.5 mEq/L, 181 
1,418 patients (85.1%) had normal potassium levels (i.e. 3.5 to 5.0 mEq/L), and 134 patients 182 
(8.0%) had hyperkalemia (above 5.0 mEq/L) at baseline (table 1). Only 34 (2%) patients had 183 
potassium levels above 5.5 mEq/L. In the overall population, mean age (± SD) was 67 ± 12 years 184 
of which 77% were male. Patients with hyperkalemia were more often men, had lower heart 185 
rates and less signs of pulmonary congestion and peripheral edema. Estimated GFR was 186 
significantly lower in patients with hyperkalemia and patients with high serum potassium were 187 
more often on MRA treatment. 188 
 A difference in prevalence of hyper- and hypokalemia across Europe is depicted in figure 189 
1A and 1B. Hyperkalemia was particularly prevalent in Slovenia (19%), Poland (13%), Serbia 190 
(12%) and Greece (11%) (figure 1A). After correction for potential confounders (i.e. renal 191 
function, history of diabetes mellitus, history of hypertension, fraction target dose of ACEi/ARB, 192 
beta-blocker, and MRA and uptake of diuretics (yes/no) at baseline), rates of hyperkalemia 193 
were highest in Slovenia, followed by Poland, Serbia, and Greece (P for all<0.05). Highest rates 194 
of hypokalemia were found in the Netherlands (P<0.05) (supplementary table 1A and 1B). 195 
Differences in listed characteristics between European countries are displayed in 196 
supplementary table 2.  197 
  During 9 months’ follow-up potassium levels increased (0.16 ± 0.66 mEq/L, p<0.001) 198 
and 523 (57%) of patients experienced an increase of potassium levels between baseline and 9 199 
months, while 319 (35%) of patients had a decrease in potassium. At 9 months, 21 patients 200 
(2.3%) had potassium levels below 3.5 mEq/L, 786 patients (85.4%) had normal potassium 201 
levels (i.e. 3.5 to 5.0 mEq/L), and 113 patients (12.3%) were patients with hyperkalemia (above 202 
5.0 mEq/L). Of patients with hypokalemia at baseline, 53.5% also had available data at 9 203 
months. In case of normokalemia and hyperkalemia at baseline, this was 55.6% en 50.7% at 9 204 
months respectively (supplementary table 3).  205 
 206 
Association of potassium and uptitration of guideline directed medication 207 
After 9 months, uptitration of ACEi/ARB was successful in a total of 401 patients (24.1%). For 208 
beta-blockers, successful uptitration was seen in 278 (16.7%) patients (supplementary figure 2). 209 
Results of logistic regression analyses are shown in figure 2 and supplementary figure 3. Higher 210 
serum potassium at baseline was associated with lower odds of successful uptitration at 9 211 
months in univariable analyses (OR 0.77; 95%CI 0.62–0.95; p=0.016; per increment of 1.0 mEq/L 212 
potassium). Also after correcting for clinically relevant confounders (i.e. age, sex, eGFR, systolic 213 
blood pressure, diabetes mellitus, and beta-blocker usage at 9 months), higher potassium levels 214 
at baseline showed a significant association with less successful uptitration (OR 0.80; 95%CI 215 
0.64–0.99; p=0.043). When correcting for the previously published uptitration model, higher 216 
potassium levels at baseline were still associated with lower odds of successful uptitration (OR 217 
0.70; 95%CI 0.51–0.98; p=0.035). After excluding patients already on ACEi/ARB target dose, 218 
potassium remained predictive for successful uptitration when correcting for both the 219 
uptitration model (OR 0.52; 95%CI 0.35–0.78; p=0.002) and model 3 (OR 0.66; 95%CI 0.50-0.87; 220 
p= 0.003). Further adjustment by MRA uptake at target dose (yes/no) did not change the 221 
association between baseline potassium levels and ACEi/ARB uptitration when correcting for 222 
the uptitration model (OR 0.54 95%CI 0.35–0.81; p=0.003) as well as for model 3 (OR 0.68; 223 
95%CI 0.51-0.89; p= 0.006). No interaction was observed between potassium and renal function 224 
for successful uptitration (Pinteraction 0.988) suggesting that the association between 225 
hyperkalemia and uptitration is similar across the renal function spectrum. In sensitivity 226 
analysis, baseline serum potassium was univariable associated with uptitration success of 227 
ACEi/ARB (OR 0.81; 95%CI 0.67–0.98; p=0.031). However, this was attenuated after 228 
multivariable adjustment (p=0.086). As expected, no association was found between baseline 229 
potassium levels and uptitration of beta-blockers. Higher serum potassium levels at 9 months 230 
were not associated with successful uptitration of ACEi/ARB or beta-blockers (supplementary 231 
figure 3). A potassium increase over 9 months was associated with successful uptitration of 232 
ACEi/ARB (OR 1.37; 95%CI 1.09-1.72; p= 0.008), but not for beta-blockers.  233 
  234 
Potassium and outcome 235 
Results of survival analyses are presented in figure 3a/b, supplementary figure 4, and Table 2. 236 
Overall, 627 (37.6%) patients reached the combined endpoint at 2 years. Hypo- and 237 
hyperkalemia at baseline or potassium analyzed on a continuous scale were not associated with 238 
worse outcomes (Table 2). Similarly, a change between potassium levels at baseline and 9 239 
months or potassium levels at 9 months were not significantly related to outcome. When used 240 
as a continuous variable, potassium change during 9 months was not associated with outcome 241 
(HR 0.98; 95%CI 0.81-1.19; p=0.844). Potassium levels at baseline, a change of potassium during 242 
uptitration or potassium levels after uptitration, did not attenuate the beneficial effects of 243 
successful uptitration of ACEi/ARBs or beta-blockers (Pinteraction for all >0.5).  244 
 245 
Discussion 246 
This study shows that low and high serum potassium levels are common among patients with 247 
HFrEF. Potassium levels above 5.0 mEq/L were observed in 8% of HFrEF patients across Europe 248 
and being particularly prevalent in Eastern Europe and Greece. Furthermore, higher baseline 249 
potassium levels were an independent predictor of unsuccessful uptitration of ACEi/ARBs in 250 
HFrEF patients. Potassium levels or changes in potassium levels during uptitration were not 251 
associated with worse outcomes. Furthermore, a potassium increase during uptitration did not 252 
attenuate the beneficial effects of uptitration of ACEi/ARBs. The findings of this study might 253 
have implications for clinical practice, suggesting that lowering potassium levels in patients with 254 
hyperkalemia might lead to improved guideline directed treatment with ACEi and ARB. These 255 
data are important considering the availability of new potassium lowering drugs (19,20). 256 
 Our study shows an overall rate of baseline potassium abnormalities of 6.9% and 8.0% 257 
for hypo- and hyperkalemia respectively. Our results show a difference in prevalence of 258 
potassium abnormalities between European countries, even after rigorous multivariable 259 
correction, which might reflect differences in health systems or local practice (18). Our findings 260 
are in line with earlier reports from the Patients Hospitalized with acute heart failure and 261 
Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion (PROTECT) trial 262 
(6% and 9% respectively) and 6.7% and 3.3% in the Coordinating Study Evaluating Outcomes of 263 
Advising and Counseling Failure (COACH) trial (14). Overall, potassium levels increased during 264 
uptitration of ACEi/ARB, with 2.3% of patients having hypokalemia and 12.3% of patients having 265 
hyperkalemia at 9 months. During 9 months of follow-up, a significant increase of potassium 266 
was seen in the majority of patients (57.4%) and can be explained by the actively increased 267 
doses of ACEi and ARB. Unfortunately, the study design did not allow for analysis on early 268 
changes (e.g. <1 month) after dose adjustments.  269 
In this study, higher potassium levels at baseline were associated with less uptitration of 270 
ACEi/ARB. This suggests that HF patients with hyperkalemia at the start of therapy are at 271 
greater risk for lower doses or discontinuation of ACEi/ARB, which impede outcomes (6,18). 272 
This is in line with earlier reports from a general patient population where high potassium levels 273 
were found to be responsible for a significant proportion of discontinuation or lowering of 274 
dosage of ACEi and ARB. Here, discontinuation or lowering of dosages of ACEi/ARB were 275 
associated with more adverse outcomes (8). Also in previous results from the BIOSTAT-CHF 276 
study, sub-optimal dosages of ACEi/ARB were associated with worse outcomes in HF patients 277 
(18). This suggests that lower dosages and/or discontinuation of ACEi/ARB due to high 278 
potassium levels severely impede outcomes. 279 
Hypokalemia at baseline or at 9 months was not associated with worse outcomes. This is 280 
in line with earlier reports from the COACH, PROTECT and EVEREST trials, where potassium also 281 
did not show an independent association with outcome (14,21). Nevertheless, reports on the 282 
association of potassium with outcome are mixed. Previous results of post-hoc analyses 283 
performed in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure 284 
(EMPHASIS-HF) trial showed that hypokalemia (<4.0 mEq/L) is associated with adverse 285 
outcomes and amplified the beneficial effect of eplerenone (22,23). Additionally, a propensity 286 
matched study from Ahmed et al. showed that hypokalemia is associated with more adverse 287 
outcomes (22). In another sub-analysis of the Digitalis Investigation Group trial, Bowling et al. 288 
shows that this was also true for HF patients with CKD and that potassium also predicts a 289 
combined endpoint of all-cause mortality and HF rehospitalizations (24). However, it has been 290 
suggested that the association of hypokalemia with adverse outcomes reflect lower usage of 291 
MRA or higher diuretic usage and dosage, on which data was often not available in previous 292 
reports (22,24-26).  293 
Regardless of its association with outcome, potassium levels did not attenuate the 294 
beneficial effects of ACEi/ARB and beta-blockers. Previously, results from the Randomized 295 
Aldactone Evaluation Study (RALES) showed that hyperkalemia was associated with higher 296 
mortality rates, but did not interfere with the beneficial effects of spironolactone (9). The 297 
EMPHASIS-HF trial showed that the favorable effects of eplerenone on outcome did not differ 298 
for hyperkalemic compared to normokalemic patients (25). Additionally, a sub-analysis from 299 
the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 300 
trial showed that potassium levels also did not interfere with the beneficial effects of 301 
Candesartan (27). The findings of the current study confirm results of the post-hoc analysis of 302 
the CHARM trial, but also show that potassium levels do not interfere with the beneficial effects 303 
of ACEi/ARB uptitration. Previously, Lund et al. discussed the association between ACEi/ARB 304 
usage and renal function, indicating that even in HF patients with severe renal insufficiency, 305 
administering ACEi/ARB improves outcome (28,29). Nevertheless, it should be noted that 306 
potassium levels as well as increases of potassium levels during uptitration took place within 307 
the relative “normal” range of potassium levels of 3.0 mEq/L and 5.5 mEq/L. Additionally, our 308 
study shows for the first time that potassium increases during uptitration of ACEi and ARBs do 309 
not interfere with the beneficial effects of these lifesaving therapies.  310 
 311 
Study limitations 312 
This is a post-hoc analysis, which comes with the usual limitations of selection bias. Potassium 313 
levels were only measured twice, at baseline and at 9 months of follow-up. A non-repetitive 314 
measurement could falsely positive diagnose a HF patient with hyperkalemia. Repeated 315 
measurements could correct for this deviation, but were not available. Unfortunately, 316 
potassium levels were not monitored after the first 3 months of active uptitration. This would 317 
provide additional data on potassium fluctuations over time. Additionally, patients with no 318 
potassium measurement at 9 months could have died, suggesting caution in interpreting data 319 
on potassium and outcome at 9 months. Furthermore, we did not have any information about 320 
potassium supplementation as well as on diuretic dosages, which might interfere with 321 
potassium levels.   322 
Conclusion 323 
Potassium abnormalities are prevalent among HF patients. Higher potassium levels are 324 
associated with lower rates of successful uptitration of ACEi/ARBs. Potassium abnormalities are 325 
not related to adverse outcomes and do not attenuate the beneficial effects of successful 326 
uptitration of ACEi/ARBs.   327 
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 Figure legends 439 
Figure 1. Incidence levels of hyperkalemia (A) and hypokalemia (B) per country 440 
Figure 2. Odds Ratios (95% CI) for successful uptitration of ACEi/ARB depicted for baseline potassium (as 441 
continuous variable). Model 1: Corrected for age, sex, and eGFR. Model 2: Corrected model 1, systolic blood 442 
pressure, and diabetes mellitus. Model 3: Corrected for model 2 and beta-blocker usage at 9 months. Uptitration 443 
Model: Corrected for BIOSTAT-CHF uptitration model Sex, BMI, eGFR, alkaline phosphatase, and country of 444 
inclusion 445 
Figure 3. Combined endpoint of all-cause mortality and HF-hospitalization rates stratified by serum potassium 446 
levels in mEq/L at baseline (A) and 9 months (B). 447 
 448 
 449 
  450 
Table 1. Baseline characteristics 451 
Values are given as proportions, means (±SD) or medians (IQR)  452 
ACEi = Angiotensin-Converting Enzyme Inhibitors, ARB = Angiotensin Receptor Blockers, BMI = Body Mass Index, BNP = Brain 453 
Natriuretic Peptide, COPD = Chronic Obstructive Pulmonary Disease, CRP = C-reactive protein, eGFR = estimated Glomerular 454 
Filtration Rate, LVEF = Left Ventricular Ejection Fraction, MRA = Mineralocorticoid Receptor Antagonists, NT-proBNP = N-Terminal 455 
prohormone of Brain Natriuretic Peptide, NYHA = New York Heart Association, SBP = Systolic Blood Pressure. 456 
* Extent of peripheral edema was determined in 1,367 patients. 457 
^ Serum NT-proBNP levels were determined in 736 patients. 458 
Variables 
(proportions %)  
Total cohort  
(n=1,666)  
Pot < 3.5  
(n=114)  
3.5 ≤ Pot ≤ 5.0  
(n=1,418)  
Pot > 5.0  
(n=134)  
p-value  Trend  
Demographics 
Potassium levels (mEq/L) 4.3 (3.9 – 4.6) 3.2 (3.1 – 3.4) 4.3 (4.0 – 4.5) 5.4 (5.2 – 5.5) NA NA 
Age (years)  69 (60 – 76) 69 (63 – 76) 68 (59 – 77) 70 (62 – 75) 0.808 0.974 
Men  1,275 (77) 69 (61) 1,101 (78) 105 (78) <0.001  0.002  
BMI (kg/m2)  26.9 (24.1 – 30.4)  26.7 (24.2 – 31.4)  26.9 (24.0 – 30.4)  27.0 (24.2 – 30.1)  0.688  0.726  
Heart rate (/min)  76 (68 – 90)  80 (70 – 97)  77 (67 – 90)  75 (68 – 90)  0.019  0.020  
LVEF (%)  27 ± 7  27 ± 7  27 ± 7  28 ± 7  0.434  0.134 
SBP (mmHg)  123 ± 21  126 ± 24  123 ± 21  124 ± 20  0.169  0.903  
NYHA class III-IV  557 (38)  30 (32)  484 (39)  43 (38)  0.466  0.476 
eGFR (mL/min/1.73 m2)  
- eGFR < 45 mL/min  
65.0 ± 24.1  
347 (21)  
64.2 ± 24.4  
23 (20) 
65.8 ± 24.0  
280 (20) 
56.5 ± 23.7  
44 (33) 
<0.001 
0.002  
0.015  
0.009  
Signs & symptoms 
Pulmonary congestion  854 (52) 73 (64) 712 (51) 67 (51) 0.035 0.057 
Extent of peripheral edema*  
- Not present  
- Above Knee  
  
595 (44) 
75 (5) 
  
21 (23) 
8 (9) 
  
511 (44) 
64 (6) 
  
63 (52) 
3 (2) 
  
<0.001  
0.139  
  
<0.001  
0.047  
Medical history 
Diabetes mellitus  529 (32) 34 (30) 447 (32) 48 (36) 0.534 0.297 
Myocardial infarction  641 (38) 37 (32) 555 (39) 49 (37) 0.330 0.574 
Atrial fibrillation  713 (43) 49 (43) 615 (43) 49 (37) 0.314 0.272 
Hypertension  976 (59) 71 (62) 826 (58) 79 (59) 0.700 0.632 
eGFR <60  747 (45) 52 (46) 614 (43) 81 (61) 0.001 0.012 
COPD  288 (17) 21 (18) 237 (17) 30 (22) 0.238 0.352  
Laboratory  
Hemoglobin (g/dL)  13.4 ± 1.9  13.0 ± 1.8 13.4 ± 1.9  13.3 ± 1.8  0.069 0.232 
Erythrocytes (10e12/L)  4.5 (4.1 – 4.9)  4.4 (4.1 – 4.9)  4.5 (4.1 – 4.9)  4.6 (4.1 – 5.0)  0.817 0.632 
Platelets (10e9/L)  214 (173 – 258)  209 (171 – 261)  212 (173 – 257)  228 (187 – 281)  0.019 0.023 
NT-proBNP (ng/L)^
 4447 (2359 – 8824)  4132 (2621 – 7839)  4402 (2250 – 8522)  5947 (3211 – 11124)  0.068 0.155 
CRP (mg/L)  12.9 (5.5 – 26.4)  16.5 (8.2 – 30.4)  12.9 (5.4 – 26.4)  10.2 (4.5 – 19.1)  0.002 0.001  
Creatinine (µmol/L)  102 (84 – 127)  99 (77 – 124) 101 (83 – 126)  115 (91 – 150)  <0.001  <0.001  
Iron (µmol/L)  8 (5 – 13)  8 (5 – 13)  8 (5 – 13)  9 (6 – 13)  0.080 0.028 
Medication 
ACE-I/ARB 1,229 (74) 83 (73) 1,046 (74) 100 (75) 0.949 0.746 
Beta-blocker  1,390 (83) 91 (80) 1,190 (84) 109 (81) 0.419 0.822 
MRA 920 (55) 52 (46) 783 (55) 85 (63) 0.019 0.005 
Diuretics  1,665 (100) 114 (100) 1,417 (100) 134 (100) 0.916 0.975 
Digoxin 302 (18) 12 (11) 271 (19) 19 (14) 0.034 0.578 
Table 2. Cox proportional hazard regression model for the analysis of event rates for the combined endpoint (all-459 
cause mortality + HF-hospitalizations) in HF patients stratified by potassium levels on baseline, 9 months, and 460 
potassium change. 461 
 (n of patients ; n of event) 
<3.5 mEq/ L 3.5-5.0 mEq /L >5.0 mEq /L 
(114 ; 46) (1,418 ; 530) (134 ; 51) 
Baseline HR (CI), p   HR (CI), p 
Univariable 1.10 (0.83-1.47) 0.493 ref 1.01 (0.77-1.31) 0.968 
Model 1 1.11 (0.83-1.48) 0.493 ref 0.90 (0.69-1.18) 0.448 
Model 2 1.12 (0.84-1.50) 0.430 ref 0.88 (0.67-1.15) 0.353 
Model 3 1.13 (0.84-1.51) 0.419 ref 0.89 (0.68-1.17) 0.406 
9 months (21 ; 12) (786 ; 212) (113 ; 43) 
Univariable 1.65 (0.61-4.48) 0.328 ref 1.34 (0.80-2.24) 0.270 
Model 1 1.85 (0.68-5.04) 0.231 ref 1.22 (0.72-2.05) 0.466 
Model 2 1.75 (0.63-4.81) 0.280 ref 1.19 (0.70-2.01) 0.518 
Model 3 1.97 (0.71-5.49) 0.193 ref 1.19 (0.70-2.01) 0.513 
Change 
Decrease No change Increase 
(319 ; 103) (78 ; 17) (523 ; 146) 
Univariable 1.26 (0.96-1.65) 0.101 ref 1.23 (0.93-1.64) 0.148 
Model 1 1.25 (0.95-1.65) 0.105 ref 1.17 (0.88-1.56) 0.275 
Model 2 1.27 (0.96-1.66) 0.091 ref 1.15 (0.87-1.54) 0.328 
Model 3 1.23 (0.94-1.62) 0.135 ref 1.15 (0.86-1.53) 0.341 
 462 
Model 1: Corrected for age, sex, and eGFR 463 
Model 2: Corrected for age, sex, eGFR, systolic blood pressure, and diabetes mellitus 464 
Model 3: Corrected for the age, sex, eGFR, systolic blood pressure, and diabetes mellitus, ACEi/ARB usage at 9 465 
months, or beta-blocker usage at 9 months 466 
 467 
 468 
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 470 
 471 
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 474 
 475 
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